China has officially approved the world’s first invasive Brain-Computer Interface (BCI) medical device for commercial and clinical use. The device, developed by Neuracle Medical Technology (Shanghai) Co., Ltd., is an implantable system designed to assist patients in compensating for hand motor function loss.
The National Medical Products Administration (NMPA) recently completed the registration clearance, allowing the device to be launched commercially. This approval marks a milestone in the clinical application of BCI technology, which connects the brain directly with external devices to restore or enhance motor function.
Experts say this approval paves the way for advanced rehabilitation options for patients with neurological impairments. The invasive BCI device is expected to open new avenues in medical technology, patient care, and research, positioning China at the forefront of cutting-edge neurotechnology development.
Related stories:
